BAMF
BPMC

BI Asset Management Fondsmaeglerselskab’s Blueprint Medicines BPMC Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-988
Closed -$87K – 769
2025
Q1 		$87K Buy
+988
New +$96.4K ﹤0.01% 704
2024
Q1 		– Sell
-1,029
Closed -$95K – 730
2023
Q4 		$95K Buy
+1,029
New +$66.7K ﹤0.01% 686

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's BPMC Position: Q2 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 988 shares — an estimated $87K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in BPMC in Q4 2023 and held it in 2 quarters. The position peaked at $95K in Q4 2023. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 988 Blueprint Medicines shares in Q2 2025, an estimated $87K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Blueprint Medicines in Q4 2023 and held it in 2 quarters.
  • BI Asset Management Fondsmaeglerselskab's Blueprint Medicines position peaked at $95K in Q4 2023.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2025, filed 14 Aug 2025.